Unknown

Dataset Information

0

Targeted therapy in ovarian cancer.


ABSTRACT: Among female-specific cancers worldwide, ovarian cancer is the leading cause of death from gynecologic malignancy in the western world. Despite radical surgery and initial high response rates to first-line chemotherapy, up to 70% of patients experience relapses with a median progression-free survival of 12-18 months. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian cancer. This review aims to assess current understanding of targeted therapy in ovarian cancer and evaluate the evidence for targeting growth-dependent mechanisms involved in its pathogenesis. Of the many targeted therapies currently under evaluation, the most promising strategies developed thus far are antiangiogenic agents and PARP inhibitors.

SUBMITTER: Lim HJ 

PROVIDER: S-EPMC5384518 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted therapy in ovarian cancer.

Lim Hui Jun HJ   Ledger William W  

Women's health (London, England) 20160524 3


Among female-specific cancers worldwide, ovarian cancer is the leading cause of death from gynecologic malignancy in the western world. Despite radical surgery and initial high response rates to first-line chemotherapy, up to 70% of patients experience relapses with a median progression-free survival of 12-18 months. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian cancer. This review aims to assess current understanding of targeted therapy in ova  ...[more]

Similar Datasets

| S-EPMC3253450 | biostudies-other
| S-EPMC2814233 | biostudies-literature
| S-EPMC4369418 | biostudies-literature
| S-EPMC8235073 | biostudies-literature
| S-EPMC6896744 | biostudies-literature
| S-EPMC4324539 | biostudies-literature
| S-EPMC3255291 | biostudies-literature
| S-EPMC7409335 | biostudies-literature
| S-EPMC4688128 | biostudies-literature
| S-EPMC7297651 | biostudies-literature